Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | FPR2 | P25090 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 3/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659945 | 0.90 | TSHR (0.56) | TSHRFPR2NPC1ALDH1A1MAPT | |
| SCHEMBL3713752 | 0.90 | FPR2 (0.57) | TSHRFPR2MAPTSMN1; SMN2KMT2A | |
| SCHEMBL3660710 | 0.90 | KMT2A (0.66) | FPR2MAPTKMT2AMEN1CRHBP | |
| SCHEMBL3658552 | 0.88 | FPR2 (0.56) | FPR2SMN1; SMN2KMT2AMEN1TDP1 | |
| SCHEMBL3662076 | 0.81 | KMT2A (0.55) | MAPTKMT2AMEN1CRHBPCRHR2 | |
| SCHEMBL3659938 | 0.80 | KMT2A (0.61) | FPR2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL28788580 | 0.80 | KMT2A (0.49) | FPR2NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL3660498 | 0.80 | KMT2A (0.61) | FPR2MAPTKMT2AMEN1CRHBP | |
| SCHEMBL3660786 | 0.80 | KMT2A (0.57) | TSHRFPR2ALDH1A1MAPTHTT | |
| SCHEMBL3655610 | 0.77 | MEN1 (0.65) | LMNAKMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101827840-A | Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators | NOVARTIS AG | 2010-09-08 | — | — | CN | claimed |
| EP-2212314-A1 | IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | claimed |
| WO-2009050200-A1 | IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | claimed |
| US-20090099243-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | claimed |
| CN-101827840-A | Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators | NOVARTIS AG | 2010-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099243-A1 | ORGANIC COMPOUNDS | SLCO4C1, SLCO1B1, SLCO1B3 | TSHR 3827/4885FPR2 1224/4885NPC1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.